PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.89
0.5–0.75x TRAW's 2.83. Martin Whitman would question if short-term obligations are sufficiently covered.
1.89
0.5–0.75x TRAW's 2.83. Martin Whitman might be concerned about coverage if a crisis hits.
1.73
0.5–0.75x TRAW's 2.74. Martin Whitman would question if short-term obligations are too high relative to cash.
No Data
No Data available this quarter, please select a different quarter.
-13.15
Negative short-term coverage while TRAW shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.